SalioGen Therapeutics, a company that raised $135 million to develop a new gene-editing technology, has instituted widespread layoffs and is scaling back its ambitions, according to a person familiar with the situation and employee posts on social media.
It is the latest in a series of retrenchments by high-profile gene-editing companies. A spokesperson for SalioGen declined to comment.
Launched in 2021, SalioGen was among a group of new startups developing technology for inserting full-length genes into patients — a feat that can’t readily be accomplished with older approaches based on the gene-editing technology CRISPR.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in